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p73 (encoded by TP73 gene) is a p53 related protein that functions as a transcriptional factor. Similarly to p53,
following DNA damage, p73 is stabilized and activated and controls expression of target genes that are
involved in the regulation of cycle arrest and apoptosis. However, great complexity to the function of this gene
is given by the wide range of its non-tumor-related roles, which include neurological development, ciliogenesis
and fertility. From the structural point of view, p73 displays an intricate range of regulations because it can be
expressed both as an N-terminally deleted dominant-negative isoforms and as multiple alternatively spliced C-
terminal isoforms, which can include or not a sterile alpha motif domain. More is known about the functions of
the N-terminal isoforms of p73 (TAp73 and ΔNp73) and their opposing pro- and anti-apoptotic roles, whereas
the functional differences of the distinct C-terminal splice forms of p73 are very far away from been defined.
Here we summarize the current available literature regarding p73 C-terminal isoforms and the contribution of
the sterile alpha motif domain to p73 function, trying to provide an unified view in this complex and sometime
controversial field. Current data indicate that the full-length, TAp73α, is the major, if not the exclusive, isoform
detected in physiological systems, indicating that detailed spatio-temporal expression analysis and functional
studies are highly demanded to support a physiological role for the p73 alternative splicing. With this article,
we also aim to emphasize the need to further investigation on the topic, refocusing the attention on what we
believe are the most relevant unanswered questions.
© 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).p73: a p53 family member
Greater than 30 years have passed since the
discovery of p53, and it still remains one of the most
studied proteins in cancer fields and one of the most
powerful tumor suppressors. Given its crucial func-
tion, p53 was suitably named the “guardian of the
genome”. Two p53-related genes p73 and p63 were
discovered approximately 20 years ago [1,2], giving
rise to the p53 family.
A major functional similarity of this family of
transcriptional factors is the ability to execute the
cellular response to genotoxic stress. Upon DNA
damage, following slightly different mechanisms, p53,
p63 andp73 are stabilized andactivated, andpromote
regulation of a shared transcriptional signature that
results in cell cycle arrest, attempt to repairDNAand, ifthor(s). Published by Elsevier Ltd. This is
g/licenses/by/4.0/).needed, eventually apoptosis [3,4]. The fact that this
signaling is common to all the family members is
suggestive that this might be the evolutionary most
ancient function. The oldest family member, p63
indeed made its appearence in evolution to preserve
genome stability of female germ cells, a role that p63
still kept in mammals and that probably evolved in the
tumor suppression function of p53, when more
complex organisms required preservation of the
somatic cells genome to prevent cancer [5]. However,
p63 and p73 proteins each have very distinct and
specific DNA damage-independent roles: p63 is a
master regulator of epidermal development and
homeostasis [6–9], whereas, as detailed in the
following sections of this review, the p73-knockout
has revealed an unexpected role for p73 inan open access article under the CC BY license
J Mol Biol (2018) 430, 1829–1838
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ciliogenesis [12–14].
From the structural point of view, the family members
are also very similar. However, the presence of sterile
alpha motif (SAM) at the C-terminal of p73 and p63
proteins increases the structural complexity of these
members and might account for the unique signaling
network of regulators and transcriptional targets [4]. All
the family members are expressed as N-terminally
containing (TA) or deleted (ΔN) isoforms and multiple
alternative splicings at the 3′ region of the pre-RNAgive
rise to C-terminal isoforms, which for p63 and p73 can
contain or exclude theSAMdomain. TheC-terminal of
p63 has been widely studied in physiological and
pathological contexts. Heterozygous mutations in
TP63 gene are causative of a group of autosomal
dominant human conditions, associated with combi-
nations of ectodermal dysplasia, orofacial clefting and
limb malformations [15]. A particular subgroup of
these, the ankyloblepharon-ectodermal defects-cleft
lip/palate syndrome, correlates with mutations clus-
tered in the C-terminal region of p63 protein, generally
involving amino acid substitutions in SAM domain or
TI domain [15]. Deletion of the p63 C-terminus inmice
also leads to ectodermal malformation and hypopla-
sia, accompanied by a reduced proliferative capacity
of epidermal progenitor cells [16]. The study of p63
SAM domain has also led to identification of potential
key interactions, including lipids [17], but the full
mechanistic details of its contribution to p63 functions
are still under investigation. The 3′ region of p73 is
even more complicated as it can undergo a higher
number of alterative splicing, producing at least seven
splice forms (α, β, γ, δ, ε, ζ, η), whereas p53 and p63
can produce only 2 or 3 isoforms (α, β, γ) [4].
The focus of this article is to review all the literature
regarding the function of the wide range of p73 C-
terminal isoforms. More information is available about
the functions of theN-terminal isoforms of p73 (TAp73
and ΔNp73) and their opposing pro- and anti-
apoptotic roles. Distinct contributions of the different
p73C-terminal isoforms to the p73 function are indeed
unclear. However, this information is important to
understand the potential role of each isoform to
development, oncogenesis and other human pathol-
ogies. This article will try to point attention of relevant
scientific community on the need of further under-
standing of the C-terminal isoforms of p73, summa-
rizing the available literature and revising old findings
in the light of more recent progress.We also aim to set
priorities for future studies on the topic.Structure of p73 gene
The TP73 (Tumor Protein p73) gene consists of 15
exons and is located on the short arm of chromo-
some 1 (1p36.33) [1]. The TP73 gene gives rise to
different mRNAs, which are translated into severaldifferent proteins. Various mRNAs arise due to the
use of two alternative promoters, namely P1 in the
5’UTR upstream of exon 1 and P2 located between
exons 3 and 4, and the alternative splicing of the N-
terminal and C-terminal (Fig. 1a–c). Transcription
from two different promoters on the TP73 gene results
in the generation of TAp73 and ΔNp73 (Fig. 1a). The
former contains a transactivation (TA) domain, which
is encoded by exons 2 and 3. In contrast, ΔNp73 is
shorter and does not contain TA domain. The other
group of N-terminal truncated p73 isoforms arises
from alternative splicing of the N-terminus of the
transcript generated from the P1 promoter (ΔEx2p73,
ΔEx2/3p73 and ΔN′p73) [18].
Isoform-specific knockout mouse models for the
N-terminal isoforms demonstrated that TAp73 de-
pletion facilitates cancer development and leads to
important developmental issues, whereas depletion
of ΔNp73 reduces tumor growth [10,19]. Expression
of a TAp73 is also important in neurogenesis and
pheromonal signaling and for normal dynamics of
cerebral fluid [11]. Evidence suggests that TAp73 is
required also for proper differentiation of multiciliated
cells by directly regulating transcription factor Fork-
head box J1 (Foxj1), which is required for the
transactivation of genes encoding proteins involved
in ciliogenesis [13]. p73-null and TAp73-null mice
display defective ciliogenesis in upper respiratory
airways, associated with impaired clearance of
inhaled pollutants and pathogens from airways [14].
Many splicing events occur at the 3′ end, in the
part of the sequence that is not found in the p53
gene. At least seven different 3′ terminal transcripts
are known (α, β, γ, δ, ε, ζ, η) to be generated at the C-
terminus and express only one of two N terminal
sequences (TA or ΔN) [20] (Fig. 1a). Collectively, the
TP73 gene expresses at least 29 different tran-
scripts, but it remains uncertain how many of these
transcripts are truly expressed as proteins (some are
shown in Fig. 1b, c). Carboxy-terminal isoforms are
due to alternative splicing of exons 11, 12 and 13,
which code for the SAM domain. Given that the p53
gene lacks the SAM domain, it is likely that the SAM
domain is important for the differential activities of
p73. p73α is the only isoform that contains a fully
functional SAM domain. The p73β, p73γ, p73δ and
p73η isoforms are truncated forms of full-length
p73α, so the alternative reading frame that is created
by splicing events generates a STOP codon. The
p73α transcript includes exons 1–14, whereas the
p73β transcript lacks exon 13. The p73γ isoform
contains all the exons coding for the SAM domain,
but the splicing event at exon 11 creates a long
alternative reading frame that leads to a shift of the
reading frame formed from a different carboxyl
terminus by a premature STOP codon [21]. The
p73δ isoform lacks exons 11–13 and thus most of
the carboxy-terminal region. Because of this feature,
it is more similar to p53 than other p73 isoforms. The
Fig. 1. A schematic representation of the human TP73 gene structure and protein domains. (a) The TP73 gene consists
of 15 exons (white, untranslated region). Several p73 isoforms are expressed due to the usage of alternative promoters
(P1 and P2 arrows, isoforms TAp73 and ΔNp73) and splicing sites (dotted lines, N-terminal isoforms: ΔEx2, ΔEx2/3, ΔN′;
C-terminal isoforms: α, β, γ, δ, ε, ζ, η). TA, transactivation domain; DBD, DNA-binding domain; OD, oligomerization
domain; SAM domain, sterile alpha motif domain. (b) Schematic representation of genomic organization of C-terminal p73
isoforms (α, β, γ, δ, ε, ζ, η). (C) Some possible p73 protein isoforms: TAp73α, TAp73β, TAp73γ, TAp73δ, TAp73ε, TAp73ζ,
TAp73η, ΔNp73α, ΔNp73β and ΔNp73γ isoforms. TA, transactivation domain; DBD, DNA-binding domain; OD,
oligomerization domain; SAM domain, sterile alpha motif domain.
1831Review: p73 Alternative Splicingp73ε isoform has a carboxyl-terminal region that is
composed of parts of the p73γ and p73α reading
frames (it lacks exons 11 and 13). The p73ζ isoform
has an internal deletion of exons 11 and 12.
Therefore, it contains most of the SAM domain,
although it lacks several residues that seem to be
fundamental for stability and functionality. p73η is
closely related to p73α but differs at exon 14.p73 SAM domain and transcriptional
activity
p73α is the only isoform that contains a fully
functional SAM domain. This has been described asa possible protein–protein interaction domain and
might contribute to the control of p73 transcriptional
activity [22,23]. NMR spectroscopy resolved the
three-dimensional structure of this domain from
human p73. Residues 487 ± 554 form a 5-helix
bundle with recapitulate structures of Ephrin receptor
tyrosine kinases SAMdomains, whose involvement in
protein–protein interaction is well characterized and
associated with regulation of the transcription [23,24].
This structural similarity supports the arguments that
p73 SAM domain is responsible for interactions
involved in regulation of p73 transcriptional capability.
However, the pattern of surface residues of p73
(spanning amino acids 487 ± 554) appears unrelated
to that of the Eph receptors and mostly recapitulates
1832 Review: p73 Alternative Splicingp63 SAM domain surface. This might indicate that
p63/p73 C-terminal regions could represent an
independent unique class of protein domains struc-
turally related to the SAM.
Experimental data indicate that the SAM domain
influences the transcriptional activity of p73. C-
terminally truncated p73 isoforms exhibit different
ranges of transcriptional activities. Among them, the
p73β isoform more actively induces apoptosis and is
the strongest transcriptional activator, at least
among characterized p53-target genes [25]. The
p73γ isoform exhibits high expression in testis
compared with other tissues and is a relatively
weak transactivator of p53-target genes [21,26].
Compared with other C-terminal isoforms, the p73η
isoform is exclusively detected in lymph nodes [27].
This isoform exhibits considerable potential to
transactivate p53-target genes and is comparable
to p73α and p73γ. More similar to p73α, p73δ
exhibits intermediate strength in transactivation
[21,26]. The functional role of the p73α C-terminal
region was also investigated with a series of p73α
truncation mutants. p73α(1–427) (lacking the most
COOH-terminal region including a SAM domain) and
p73α(1–548) (deleting an extreme COOH-terminal
region except a SAM domain) displayed significant
transcriptional ability on a luciferase-based reporter
assay and higher DNA binding compared to the full-
length p73α [28]. Overall these data confirmed the
potential of the p73 C-terminal region for regulation
of p73 activity.
The tetrameric state of p53, p63 and p73 has been
considered one of the hallmarks of this protein
family. p73 can form hetero-interactions with p63
and with a lesser extent aggregate with forms of
mutant p53 [21,29,30]. Remarkably, due to structural
differences, p73 cannot hetero tetramerize with wt
p53. Structural studies on the C-terminal of the
ancestral p53 family members, the Caenorhabditis
elegans and Drosophila forms, CEP-1 and Dmp53,
indicate a potential contribution of the SAM domain
present in these proteins in the oligomerization of
transcriptional factor. These additional structural
elements were necessary for the integrity of the
oligomerization domain of Dmp53 and CEP-1
proteins [31]. Remarkably, these are not present in
human p53, but make these ancestral forms
structurally closer to p63 and p73. These analyses
indicate a contribution of the SAM domain in the
stability of p73 tetramer and therefore in its tran-
scriptional ability. Although there are no data
formally proving a contribution of the SAM domain
in p73 oligomerization, these findings are suggestive
of a potential function of this domain in vertebrate
p53 family members.
Tissue-specific expression of p73 C-terminal
isoforms in mice indicates that although RNA of the
C-terminal variants can be detected virtually in all
organs, their expression is below the threshold fordetection of the corresponding protein; p73α was
indeed the only significantly expressed C-terminal
isoform [32]. These analysis leads us to speculate
that SAM domain is required for p73 developmental
functions; however, this assumption requires valida-
tion in appropriate animal models.Roles of p73 isoforms in cancer
Mutations in TP73 gene in cancer are very rare
and TP73-deficient mice lack a spontaneous tumor
phenotype [11]. However, isoform-specific knockout
mice revealed that the depletion of TAp73 predis-
poses to cancer, whereas the absence of ΔNp73
decreases tumor growth [10,19]. The relative ex-
pression of TAp73 and ΔNp73 isoforms is indeed
probably responsible for the biological outcome of
p73 expression. As a result, most studies in cancer-
related fields focus their attention on the analysis of
changes in TAp73 and ΔNp73 expression levels.
Apoptotic activities of transcriptionally active p73
isoforms (TA) are commonly inhibited by dominant
negative p73 isoforms (ΔN), which can counteract
TAp73 tetramerization or compete for promoter
binding. As a result, the relative ratio of different
p73 isoforms is crucial for the cellular response to a
chemotherapeutic agent [10,33].
Tumors and cell lines with highly expressing p73
tend to display a complex profile of up to six different
C-terminal splice variants, where p73α is still the
major form, whereas normal and breast cancer
tissues with low p73 mRNA levels exclusively
express TAp73α. However, generally the low-
expressing tissues display predominantly p73α,
whereas overexpressing tumors show a complex
pattern [34]. This is again suggestive that expression
of alpha isoform is the major outcome of TP73 gene
expression and the relevance and contribution of the
other isoforms remain unclear.
The study of p73 C-terminal function in tumori-
genesis is limited to in vitro studies largely based on
overexpression approaches. The two mostly studied
C-terminal isoforms are TAp73α and TAp73β.
Overexpression of TAp73α, TAp73β and TAp73γ
induces apoptosis in SaOs-2 cells by promoting
transcriptional regulation of PUMA and Bax and
mitochondrial translocation of Bax. Interestingly,
transactivation capability on the pro-apoptotic factors
and the extent of the apoptotic effect were largely
higher in the shortest isoforms TAp73β and TAp73γ
[3]. The p73-dependent pro-apoptotic programme
was also associated with induction of the Cip/Kip
family of cyclin-dependent kinase (CDK) inhibitor,
p57Kip2. p57Kip2 appeared to be a selective transcrip-
tional target of p73β isoform, responsible of its
programmed cell death induction [35]. However, the
biological relevance of these findings should be
revised after re-analysis of the question with more
1833Review: p73 Alternative Splicingmodern technologies, as these results might be the
consequence of overexpression at non-physiological
level of short isoforms resembling p53 structure. More
recent studies indicate that TAp73 contributes to
genomic stability of somatic and germline cells. The
interaction of TAp73α with kinetochore proteins Bub1
and Bub3 alters the mitotic checkpoints and deregu-
lation of TAp73 in cancer might therefore have an
impact on polyploidy [36,37]. TAp73 was also shown
to bind and regulate the hypoxia-inducible factor 1α
(HIF-1α). In hypoxic tumor, expression of TAp73
represses activation of HIF-1, thus limiting tumor
angiogenesis and therefore progression [30,38,39].
Additional contribution of p73 to tumor cell biology
might be mediated by its effect on the cellular
metabolism, which largely appears to support anti-
oxidant defence and anabolic processes. TAp73
expression is associated with an increased serine/
glycine synthesis, production of NADPH and GSH in
different cancer models, and glutaminase-2 (GLS-2)
and glucose-6-phosphate-dehydrogenase (G6PD)
metabolic enzymes have been described as direct
TAP73 targets [40–43]. However, a detailed analysis
of the differential effects of the C-terminal isoforms
was not conduced.
Interesting insights into the contribution of the C-
terminal region to a potential p73-related cancer
phenotype have been provided by structural studies
on the aggregation propensity of mutant p53 R175H
on p73 C-terminal isoforms. Mutations in p53 are
found inmore than 50% of all the human cancers, and
their oncogenic potential is associated with not only
the loss of function of wt p53 but also expression of
neomorphic forms of the protein originated by
missense mutations. p53 conformational mutants,
such as R175H, have been suggested to directly bind
to p73 via a co-aggregation mechanism mediated by
their unstructured DNA binding domains. This effect
was postulated to repress any p73-dependent tumor
suppression capability, resulting in more aggressive
phenotype [44,45]. Detailed mapping of the interac-
tion motif of the region of p73α identified the last few
amino acids of the protein, corresponding to a
predicted transactivation Inhibitor domain, to mediate
interaction with p53R175H. Consequentially, shorter
C-terminal isoforms, such as TAp73β, appear insen-
sitive to p53R175H, thus potentially conserving their
tumor suppression properties in p53 mutant genetic
background (Fig. 2) [46]. It still remains elusive
whether a tumor can express TAp73β at sufficient
levels and what are the underlining molecular
mechanism forcing the shift from alpha to beta.Regulation of p73 C-terminal isoforms by
selective post-translation modifications
Stabilization and activation of p53 follows a deeply
studied pattern of post-translational modificationsinvolving phosphorylation, acetylation, sumoylation
and ubiquitination, with a major regulation step
represented by the interaction with ubiquitin-ligase
MDM2, which controls its protesomal degradation
[47]. p73 does bind MDM2, but in contrast with p53,
this interaction does not mediate a control of the
stability; however, stabilization of p73 following DNA
damage and other stress appears to be the
predominant mechanism of regulation for its expres-
sion [4]. The U-box-type E3/E4 ubiquitin ligase
UFD2a was functionally associated with p73α, and
in particular, the SAM domain appears to be involved
in a physical interaction. UFD2a indeedmediates the
proteasomal turnover of p73 in a mechanism that
does not involve ubiquitination [48]. The Hect
ubiquitin-ligase, Itch, was identified as an exclusive
binding partner of p73. Upon DNA damage, Itch is
downregulated leading to an increased level of p73
[49]. However, WW domain of Itch recognizes p73
on it proline-rich (PY) domain, which is encoded by
exon 12. As a result, Itch has no effect on the
shortest p73 proteins, such as the γ and δ isoforms,
and for the same reason does not affect p53 stability
[49]. So far, Itch is the major recognized regulator of
p73 stability (Fig. 3a, b).
The PY domain of p73 is involved also in other
potentially key protein interactions. The PY domain
indeed interacts with the WW domain of with the
Yes-associated protein (YAP). The motif binds to
a 40-amino-acid structural domain known as the
WW domain that is organized to form a three-
stranded, antiparallel β sheet containing two trypto-
phan (W) residues spaced 20–22 amino acids apart
[50]. YAP enhances p73α-dependent transcriptional
activation in p53-deficient H1299 cells. YAP binds
p73α and p73β, but it does not interact with p73γ and
other shorter isoforms. In addition to this, NEDD4-
related E3 ubiquitin ligase NEDL2 can also form a
complex with the C-terminus of p73α and p73β
isoforms [51]. NEDL2 overexpression resulted in the
ubiquitination of p73, which leads to NEDL2-
mediated stabilization of p73 and enhanced p73-
dependent transcriptional activation. The C-terminal
SAM domain region of p73α is also required for
direct binding to NAD(P)H quinone oxidoreductase 1
(NQO1), which leads to it ubiquitin-independent
proteasomal degradation [52].
Activation and stabilization of p73 is associated with
other post-translational involving the C-termini. The C-
terminal lysine 627 can be covalently modified by
SUMOylation (small ubiquitin-like modifier, or SUMO).
Lysine 627 is contained in the C-terminal region of the
p73α isoform not p73β, suggesting another distinct
regulation for the individual isoforms (Fig. 3a).
SUMOylation of p73α is not required for p73 degrada-
tion, but it might facilitate subcellular relocalization and
interaction with additional partners [53]. Another
potential key interactor of the extreme C-terminus of
p73α (551–636 aa) is the receptor for activated C
Fig. 2. Aggregation propensity of p73 C-terminal isoforms with p53 mutants. The cancer hotspot mutation p53 R175H
interacts with exclusively with the C-terminal of p73α, which includes SAM and TI domains. Amino acids corresponding to
the TI domain of p73α are required for p53 R175H aggregation. Consequentially, the p73β isoform, which lacks the SAM
and TI domains, is not susceptible to the inhibition mediated by p53 R175H aggregation. This suggests that p73β might
preserve its tumor suppression ability in a p53 mutant genetic background.
1834 Review: p73 Alternative Splicingkinase-1 (RACK1). RACK1 overexpression indeed
inhibits p73α-meditated transcription and p73α-
dependent apoptosis. Deletion of theC-terminal region
of p73α enhances its transactivation ability, suggesting
that the C-terminal region of p73α exhibits a negative
regulatory ability that modulates its transcriptional
activity [26]. RACK1-mediated inhibition of p73α
suggests the possibility that RACK1acts as an adaptermolecule between the transcriptional repressor and
the C-terminal regulatory region of p73α. In addition,
the interaction of RACK1 with the C-terminal region of
p73α might alter the ability of p73α to interact with
cellular proteins that have coactivator functions.
RACK1 is currently the only player accounting for the
differential transactivation potential of TAp73α and
TAp73β.
(a)
(b)
Fig. 3. Interactors of p73α C-terminus. (A) Schematic representation of p73α C-terminus a corresponding interactors or
posttranslational modifications. SUMOylation of p73 occurs at lysine 627 (K627). NEDL2, YAP and Itch share the region of
interaction corresponding to the proline rich (PY) motif. NQO1 was described to interact with the SAM domain. RACK 1
interacts with the last few C-terminal amino acids of p73α.
1835Review: p73 Alternative SplicingConcluding remarks and future
perspective
Our current understanding indicates that various
products from TP73 genes, originated by alternative
gene promoter usage and differential splicing, might
differentially participate in complex networks that
regulate cell growth, differentiation and death.
However, still little evidence indicates proper selec-
tive mechanisms of action and pattern of expression
of the individual C-terminal isoforms. It is important to
investigate these isoforms to evaluate their contri-
bution to physiology and identify their potential roles
in human pathologies, such as cancer.
As current data indicate TAp73α as the exclusive,
or major, expressed isoform in most of the biological
system analyzed, a detailed spatio-temporal analy-
sis of all the C-terminal isoforms expression pattern
during development and tumorigenesis is critical to
support a biological relevance for alternative splic-ings. To explore specificity of interaction partners for
different C-terminal p73 isoforms and their unknown
functions, it is also necessary to develop sensitive
isoform-specific antibodies. The N-terminal isoform-
specific KO mice shed considerable light onto the
understanding of the roles and functions of these
isoforms [10,11,19]. Thus, C-terminal isoform-
specific KO mice models would be critical to unveil
their functions and the potential correlations with
human diseases. Previously uncovered common
and unique features of C-terminal isoforms of p73
represent challenges to explore specific activities
and regulation of each p73 isoform.Acknowledgments
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